Scribe Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Scribe Therapeutics Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-1.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 66% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Scribe Therapeutics Inc. made a loss over the last year. Scribe Therapeutics Inc. owes $3.85 for every $1 it owns. Scribe Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossScribe Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-2.06Scribe Therapeutics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$340 MThe total market value of all of Scribe Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeScribe Therapeutics Inc.'s net worth is negative ($165 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
3.85×Scribe Therapeutics Inc. owes $3.85 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneScribe Therapeutics Inc. does not currently pay a dividend.
Revenue growth
+87%Revenue rose 87% in the year to Dec 2025.
Profit growth
LossScribe Therapeutics Inc. made a loss in each of the last two years.
Profit margin
-42.6%Scribe Therapeutics Inc. lost $43 for every $100 of revenue.
Interest cover
Not coveredScribe Therapeutics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashScribe Therapeutics Inc. held $17 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Scribe Therapeutics Inc. owe compared with what it owns?
Scribe Therapeutics Inc. owes $3.85 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does Scribe Therapeutics Inc. pay a dividend?
No. Scribe Therapeutics Inc. does not currently pay a dividend.
Is Scribe Therapeutics Inc.'s revenue growing?
Revenue rose 87% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.